Inhibitor Therapeutics, Inc. (OTC:INTI) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on August 17, 2026.
At publication ·
Inhibitor Therapeutics, Inc. (OTC:INTI) · proxy filed
At a glance
Inhibitor Therapeutics, Inc. (OTC:INTI) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on August 17, 2026.
The Healthcare company's proxy statement provides information for shareholders ahead of the annual meeting, including board nominations, executive compensation, and proposals for shareholder vote.
Inhibitor Therapeutics, Inc.'s stock currently trades at $0.09 with a market capitalization of $6.9M.
SEC filings provide mandatory disclosures that give investors access to the same material information available to institutional investors. Reviewing Inhibitor Therapeutics, Inc.'s filings alongside price action and analyst commentary provides a more complete picture of the company's current situation.
All SEC filings for Inhibitor Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View INTI Stock Page
Browse all filings on our INTI SEC filings page.
Public companies like Inhibitor Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Current market data
OTC · INTI
$0.09
Up: +$0.01 · +17.57%
Live quote updated
